RGNX – REGENXBIO Inc.
REGENXBIO Inc.RGNX
$10.51Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $530,904,416.00
EPSttm : -3.44
REGENXBIO Inc.
$10.51
1.68%$0.18Float Short %
11.06
Margin Of Safety %
Put/Call OI Ratio
0.58
EPS Next Q Diff
1.66
EPS Last/This Y
2.31
EPS This/Next Y
-0.74
Price
10.5
Target Price
31
Analyst Recom
1.42
Performance Q
14.61
Relative Volume
0.87
Beta
1.2
Ticker: RGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | RGNX | 9.49 | 0.93 | 0.50 | 4701 |
| 2025-09-09 | RGNX | 9.89 | 0.93 | 1.00 | 4707 |
| 2025-09-10 | RGNX | 9.58 | 0.93 | 0.04 | 4707 |
| 2025-09-11 | RGNX | 9.49 | 0.90 | 0.00 | 4817 |
| 2025-09-12 | RGNX | 9.21 | 0.90 | 0.00 | 4817 |
| 2025-09-15 | RGNX | 9.07 | 0.89 | 0.03 | 4830 |
| 2025-09-16 | RGNX | 9.26 | 0.88 | 0.00 | 4856 |
| 2025-09-17 | RGNX | 9.03 | 0.88290034897247 | 0 | 4856 |
| 2025-09-18 | RGNX | 9.36 | 0.88 | 0.06 | 4868 |
| 2025-09-19 | RGNX | 8.89 | 0.88 | 0.33 | 4877 |
| 2025-09-22 | RGNX | 9.05 | 0.76 | 0.03 | 4495 |
| 2025-09-23 | RGNX | 8.92 | 0.75 | 0.33 | 4521 |
| 2025-09-24 | RGNX | 9.56 | 0.75 | 0.14 | 4524 |
| 2025-09-25 | RGNX | 9.37 | 0.75 | 3.50 | 4532 |
| 2025-09-26 | RGNX | 9.66 | 0.75 | 0.01 | 4535 |
| 2025-09-29 | RGNX | 9.85 | 0.74 | 0.04 | 4581 |
| 2025-09-30 | RGNX | 9.66 | 0.71 | 0.75 | 4664 |
| 2025-10-01 | RGNX | 9.77 | 0.71 | 2.00 | 4684 |
| 2025-10-02 | RGNX | 10.57 | 0.71 | 0.02 | 4687 |
| 2025-10-03 | RGNX | 10.44 | 0.59 | 0.33 | 5257 |
| 2025-10-06 | RGNX | 10.69 | 0.58 | 0.31 | 5189 |
| 2025-10-07 | RGNX | 10.51 | 0.58 | 4.08 | 5198 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | RGNX | 9.48 | -10.2 | 247.2 | -2.13 |
| 2025-09-09 | RGNX | 9.89 | -10.2 | 261.8 | -2.13 |
| 2025-09-10 | RGNX | 9.57 | -10.2 | 245.6 | -2.13 |
| 2025-09-11 | RGNX | 9.49 | -10.2 | 250.5 | -2.13 |
| 2025-09-12 | RGNX | 9.20 | -10.2 | 245.7 | -2.13 |
| 2025-09-15 | RGNX | 9.10 | -10.2 | 249.7 | -2.13 |
| 2025-09-16 | RGNX | 9.26 | -10.2 | 256.7 | -2.13 |
| 2025-09-17 | RGNX | 9.01 | -10.2 | 246.1 | -2.13 |
| 2025-09-18 | RGNX | 9.38 | -10.2 | 261.3 | -2.12 |
| 2025-09-19 | RGNX | 8.89 | -10.2 | 241.0 | -2.12 |
| 2025-09-22 | RGNX | 9.06 | -10.4 | 257.0 | -2.12 |
| 2025-09-23 | RGNX | 8.93 | -10.4 | 248.9 | -2.12 |
| 2025-09-24 | RGNX | 9.54 | -10.4 | 268.5 | -2.12 |
| 2025-09-25 | RGNX | 9.36 | -10.4 | 248.0 | -2.12 |
| 2025-09-26 | RGNX | 9.65 | -10.4 | 259.0 | -2.12 |
| 2025-09-29 | RGNX | 9.86 | -10.4 | 257.0 | -2.12 |
| 2025-09-30 | RGNX | 9.63 | -10.4 | 247.6 | -2.12 |
| 2025-10-01 | RGNX | 9.77 | -10.4 | 254.9 | -2.12 |
| 2025-10-02 | RGNX | 10.56 | -10.4 | 269.3 | -2.12 |
| 2025-10-03 | RGNX | 10.43 | -10.4 | 249.5 | -2.12 |
| 2025-10-06 | RGNX | 10.69 | -10.4 | 254.2 | -2.12 |
| 2025-10-07 | RGNX | 10.50 | -10.4 | 248.6 | -2.28 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | RGNX | -0.43 | -0.73 | 11.95 |
| 2025-09-09 | RGNX | -0.43 | -0.73 | 11.95 |
| 2025-09-10 | RGNX | -0.43 | -0.73 | 11.95 |
| 2025-09-11 | RGNX | -0.43 | -0.73 | 11.22 |
| 2025-09-12 | RGNX | -0.60 | -0.73 | 11.22 |
| 2025-09-15 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-16 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-17 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-18 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-19 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-22 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-23 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-24 | RGNX | -0.60 | -0.67 | 11.22 |
| 2025-09-25 | RGNX | -0.60 | -0.67 | 11.06 |
| 2025-09-26 | RGNX | -0.60 | -0.67 | 11.06 |
| 2025-09-29 | RGNX | -0.60 | -0.66 | 11.06 |
| 2025-09-30 | RGNX | -0.60 | -0.66 | 11.06 |
| 2025-10-01 | RGNX | -0.76 | -0.66 | 11.06 |
| 2025-10-02 | RGNX | -0.76 | -0.66 | 11.06 |
| 2025-10-03 | RGNX | -0.76 | -0.66 | 11.06 |
| 2025-10-06 | RGNX | -0.76 | -0.51 | 11.06 |
| 2025-10-07 | RGNX | -0.76 | -0.51 | 11.06 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.38
Avg. EPS Est. Current Quarter
-1.29
Avg. EPS Est. Next Quarter
0.28
Insider Transactions
-0.76
Institutional Transactions
-0.51
Beta
1.2
Average Sales Estimate Current Quarter
24
Average Sales Estimate Next Quarter
95
Fair Value
Quality Score
41
Growth Score
36
Sentiment Score
65
Actual DrawDown %
79.1
Max Drawdown 5-Year %
-89.4
Target Price
31
P/E
Forward P/E
PEG
P/S
3.41
P/B
2.48
P/Free Cash Flow
EPS
-3.46
Average EPS Est. Cur. Y
-2.28
EPS Next Y. (Est.)
-3.02
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-112.7
Relative Volume
0.87
Return on Equity vs Sector %
-107.4
Return on Equity vs Industry %
-93.7
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.25
EBIT Estimation
248.6
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading